News
ARQT ▼ -13.0% - Arcutis Biotherapeutics, Inc.
ARQT ▼ -13.0% - Arcutis Biotherapeutics, Inc.
$ARQT - Arcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE® (roflumilast) Cream 0.3% in Moderate to Severe Atopic Dermatitis
05-NOV-2026 08:00 AM ET
Share this post
More filings for $ARQT
ARQT ▼ -10.5% - Arcutis Biotherapeutics, Inc.Nov 4, 2026ARQT ▼ -7.5% - Arcutis Biotherapeutics, Inc.Nov 4, 2026ARQT ▼ -0.2% - Arcutis Biotherapeutics, Inc.Oct 28, 2026ARQT ▼ -0.4% - Arcutis Biotherapeutics, Inc.Oct 27, 2026ARQT ▼ -3.0% - Arcutis Biotherapeutics, Inc.Oct 21, 2026ARQT ▲ +0.9% - Arcutis Biotherapeutics, Inc.Oct 9, 2026
View full $ARQT filing history →💬 Comments
Loading comments…
Leave a comment